Aortic Counterpulsation Therapy in Patients with Advanced Heart Failure: Analysis of the TBRIDGE Registry
Abstract Background: The use of aortic counterpulsation therapy in advanced heart failure is controversial. Objectives: To evaluate the hemodynamic and metabolic effects of intra-aortic balloon pump (IABP) and its impact on 30-day mortality in patients with heart failure. Methods: Historical prospective, unicentric study to evaluate all patients treated with IABP betwen August/2008 and July/2013, included in an institutional registry named TBRIDGE (The Brazilian Registry of Intra-aortic balloon pump in Decompensated heart failure - Global Evaluation). We analyzed changes in oxygen central venous saturation (ScvO2), arterial lactate, and use of vasoactive drugs at 48 hours after IABP insertion. The 30-day mortality was estimated by the Kaplan-Meier method and diferences in subgroups were evaluated by the Log-rank test. Results: A total of 223 patients (mean age 49 ± 14 years) were included. Mean left ventricle ejection fraction was 24 ± 10%, and 30% of patients had Chagas disease. Compared with pre-IABP insertion, we observed an increase in ScvO2 (50.5% vs. 65.5%, p < 0.001) and use of nitroprusside (33.6% vs. 47.5%, p < 0.001), and a decrease in lactate levels (31.4 vs. 16.7 mg/dL, p < 0.001) and use of vasopressors (36.3% vs. 25.6%, p = 0.003) after IABP insertion. Thirty-day survival was 69%, with lower mortality in Chagas disease patients compared without the disease (p = 0.008). Conclusion: After 48 hours of use, IABP promoted changes in the use of vasoactive drugs, improved tissue perfusion. Chagas etiology was associated with lower 30-day mortality. Aortic counterpulsation therapy is an effective method of circulatory support for patients waiting for heart transplantation.
Main Authors: | , , , , , , , , , |
---|---|
Format: | Digital revista |
Language: | English |
Published: |
Sociedade Brasileira de Cardiologia - SBC
2016
|
Online Access: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2016000100026 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
oai:scielo:S0066-782X2016000100026 |
---|---|
record_format |
ojs |
spelling |
oai:scielo:S0066-782X20160001000262016-01-22Aortic Counterpulsation Therapy in Patients with Advanced Heart Failure: Analysis of the TBRIDGE RegistryBezerra,Cristiano GuedesAdam,Eduardo LealBaptista,Mariana LinsCiambelli,Giuliano SerafinoKopel,LilianeBernoche,ClaudiaLopes,Leonardo Nicolau Geisler DaudMacatrão-Costa,Milena FrotaFalcão,Breno de Alencar AraripeLage,Silvia Gelas Shock, Cardiogenic / mortality Heart Failure Chagas Cardiomyopathy Intra-Aortic Balloon Pump Heart Transplanation Counterpulsation Abstract Background: The use of aortic counterpulsation therapy in advanced heart failure is controversial. Objectives: To evaluate the hemodynamic and metabolic effects of intra-aortic balloon pump (IABP) and its impact on 30-day mortality in patients with heart failure. Methods: Historical prospective, unicentric study to evaluate all patients treated with IABP betwen August/2008 and July/2013, included in an institutional registry named TBRIDGE (The Brazilian Registry of Intra-aortic balloon pump in Decompensated heart failure - Global Evaluation). We analyzed changes in oxygen central venous saturation (ScvO2), arterial lactate, and use of vasoactive drugs at 48 hours after IABP insertion. The 30-day mortality was estimated by the Kaplan-Meier method and diferences in subgroups were evaluated by the Log-rank test. Results: A total of 223 patients (mean age 49 ± 14 years) were included. Mean left ventricle ejection fraction was 24 ± 10%, and 30% of patients had Chagas disease. Compared with pre-IABP insertion, we observed an increase in ScvO2 (50.5% vs. 65.5%, p < 0.001) and use of nitroprusside (33.6% vs. 47.5%, p < 0.001), and a decrease in lactate levels (31.4 vs. 16.7 mg/dL, p < 0.001) and use of vasopressors (36.3% vs. 25.6%, p = 0.003) after IABP insertion. Thirty-day survival was 69%, with lower mortality in Chagas disease patients compared without the disease (p = 0.008). Conclusion: After 48 hours of use, IABP promoted changes in the use of vasoactive drugs, improved tissue perfusion. Chagas etiology was associated with lower 30-day mortality. Aortic counterpulsation therapy is an effective method of circulatory support for patients waiting for heart transplantation.info:eu-repo/semantics/openAccessSociedade Brasileira de Cardiologia - SBCArquivos Brasileiros de Cardiologia v.106 n.1 20162016-01-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2016000100026en10.5935/abc.20150147 |
institution |
SCIELO |
collection |
OJS |
country |
Brasil |
countrycode |
BR |
component |
Revista |
access |
En linea |
databasecode |
rev-scielo-br |
tag |
revista |
region |
America del Sur |
libraryname |
SciELO |
language |
English |
format |
Digital |
author |
Bezerra,Cristiano Guedes Adam,Eduardo Leal Baptista,Mariana Lins Ciambelli,Giuliano Serafino Kopel,Liliane Bernoche,Claudia Lopes,Leonardo Nicolau Geisler Daud Macatrão-Costa,Milena Frota Falcão,Breno de Alencar Araripe Lage,Silvia Gelas |
spellingShingle |
Bezerra,Cristiano Guedes Adam,Eduardo Leal Baptista,Mariana Lins Ciambelli,Giuliano Serafino Kopel,Liliane Bernoche,Claudia Lopes,Leonardo Nicolau Geisler Daud Macatrão-Costa,Milena Frota Falcão,Breno de Alencar Araripe Lage,Silvia Gelas Aortic Counterpulsation Therapy in Patients with Advanced Heart Failure: Analysis of the TBRIDGE Registry |
author_facet |
Bezerra,Cristiano Guedes Adam,Eduardo Leal Baptista,Mariana Lins Ciambelli,Giuliano Serafino Kopel,Liliane Bernoche,Claudia Lopes,Leonardo Nicolau Geisler Daud Macatrão-Costa,Milena Frota Falcão,Breno de Alencar Araripe Lage,Silvia Gelas |
author_sort |
Bezerra,Cristiano Guedes |
title |
Aortic Counterpulsation Therapy in Patients with Advanced Heart Failure: Analysis of the TBRIDGE Registry |
title_short |
Aortic Counterpulsation Therapy in Patients with Advanced Heart Failure: Analysis of the TBRIDGE Registry |
title_full |
Aortic Counterpulsation Therapy in Patients with Advanced Heart Failure: Analysis of the TBRIDGE Registry |
title_fullStr |
Aortic Counterpulsation Therapy in Patients with Advanced Heart Failure: Analysis of the TBRIDGE Registry |
title_full_unstemmed |
Aortic Counterpulsation Therapy in Patients with Advanced Heart Failure: Analysis of the TBRIDGE Registry |
title_sort |
aortic counterpulsation therapy in patients with advanced heart failure: analysis of the tbridge registry |
description |
Abstract Background: The use of aortic counterpulsation therapy in advanced heart failure is controversial. Objectives: To evaluate the hemodynamic and metabolic effects of intra-aortic balloon pump (IABP) and its impact on 30-day mortality in patients with heart failure. Methods: Historical prospective, unicentric study to evaluate all patients treated with IABP betwen August/2008 and July/2013, included in an institutional registry named TBRIDGE (The Brazilian Registry of Intra-aortic balloon pump in Decompensated heart failure - Global Evaluation). We analyzed changes in oxygen central venous saturation (ScvO2), arterial lactate, and use of vasoactive drugs at 48 hours after IABP insertion. The 30-day mortality was estimated by the Kaplan-Meier method and diferences in subgroups were evaluated by the Log-rank test. Results: A total of 223 patients (mean age 49 ± 14 years) were included. Mean left ventricle ejection fraction was 24 ± 10%, and 30% of patients had Chagas disease. Compared with pre-IABP insertion, we observed an increase in ScvO2 (50.5% vs. 65.5%, p < 0.001) and use of nitroprusside (33.6% vs. 47.5%, p < 0.001), and a decrease in lactate levels (31.4 vs. 16.7 mg/dL, p < 0.001) and use of vasopressors (36.3% vs. 25.6%, p = 0.003) after IABP insertion. Thirty-day survival was 69%, with lower mortality in Chagas disease patients compared without the disease (p = 0.008). Conclusion: After 48 hours of use, IABP promoted changes in the use of vasoactive drugs, improved tissue perfusion. Chagas etiology was associated with lower 30-day mortality. Aortic counterpulsation therapy is an effective method of circulatory support for patients waiting for heart transplantation. |
publisher |
Sociedade Brasileira de Cardiologia - SBC |
publishDate |
2016 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2016000100026 |
work_keys_str_mv |
AT bezerracristianoguedes aorticcounterpulsationtherapyinpatientswithadvancedheartfailureanalysisofthetbridgeregistry AT adameduardoleal aorticcounterpulsationtherapyinpatientswithadvancedheartfailureanalysisofthetbridgeregistry AT baptistamarianalins aorticcounterpulsationtherapyinpatientswithadvancedheartfailureanalysisofthetbridgeregistry AT ciambelligiulianoserafino aorticcounterpulsationtherapyinpatientswithadvancedheartfailureanalysisofthetbridgeregistry AT kopelliliane aorticcounterpulsationtherapyinpatientswithadvancedheartfailureanalysisofthetbridgeregistry AT bernocheclaudia aorticcounterpulsationtherapyinpatientswithadvancedheartfailureanalysisofthetbridgeregistry AT lopesleonardonicolaugeislerdaud aorticcounterpulsationtherapyinpatientswithadvancedheartfailureanalysisofthetbridgeregistry AT macatraocostamilenafrota aorticcounterpulsationtherapyinpatientswithadvancedheartfailureanalysisofthetbridgeregistry AT falcaobrenodealencarararipe aorticcounterpulsationtherapyinpatientswithadvancedheartfailureanalysisofthetbridgeregistry AT lagesilviagelas aorticcounterpulsationtherapyinpatientswithadvancedheartfailureanalysisofthetbridgeregistry |
_version_ |
1756381984838385664 |